Thus, the pan-JNK inhibitor SP600125 (20 μM) and the PARP1 inhibitor BGB-290 (25 μM) were evaluated for their potential to overcome chemoresistance associated with miRNA-363-3p/DUSP10/JNK axis in DLBCL cells. Here, DUSP10 is linked to diffuse large B-cell lymphoma.